Teva Neuroscience, Inc. ("Teva Neuroscience") maintains this site www.copaxonehcp.com (the "site") for your personal information, education, and communication. While you should feel free to browse the site, please understand that your access to and use of the site is subject to the following terms and conditions ("terms and conditions") and all applicable laws. By accessing and browsing the site, you accept, without limitation or qualification, the terms and conditions and acknowledge that any other agreements between you and Teva Neuroscience concerning the site are superseded to the extent they conflict with these terms and conditions. Your use of or linking to any content of the site, except as provided in these terms and conditions, is strictly prohibited.
The site is not intended for use by persons under the age of 13. By accessing and using the site, you have indicated that you are at least 13 years old or older.
This site is intended only to provide information about COPAXONE® drug therapy. This site was intended specifically for individuals who are U.S. residents. This content has not been approved for non-U.S. residents. The information should not be considered complete and should not be used in place of a visit, call, consultation or advice of your physician or other healthcare provider. This web site does not recommend the self-management of health problems. Information obtained through this site is not exhaustive and does not cover all ailments, physical conditions or their treatment. Should you have any healthcare-related questions, please call or see your physician or other healthcare provider promptly. You should never disregard medical advice or delay in seeking it because of something you have read here.
VISITORS TO www.copaxonehcp.com ARE URGED AND ADVISED TO SEEK THE ADVICE OF A PHYSICIAN BEFORE BEGINNING ANY TREATMENT. Such individuals are specifically warned to seek professional medical advice prior to initiating any form of health treatment.
Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.
COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of
The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.
While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.